ArticleBMC cardiovascular disorders2026
Elevated red cell distribution width as a prognostic indicator in critically ill patients with atrial fibrillation and chronic kidney disease.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRed cell distribution width (RDW) has emerged as an important prognostic biomarker in various cardiovascular and renal conditions. However, its specific role in critically ill patients with coexisting atrial fibrillation (AF) and chronic kidney disease (CKD) is not well established. This study aims to evaluate the prognostic significance of RDW in this population.
methodsWe conducted a retrospective cohort study using the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database, identifying 2208 patients with concomitant AF and CKD. We assessed the association between RDW levels and 28-day and 365-day mortality using multivariable Cox regression models, Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curve and subgroup analyses.
resultsElevated RDW was independently associated with increased risks of both 28-day and 365-day all-cause mortality after multivariable adjustment (fully adjusted Hazard Ratio [HR]: 1.15 and 1.17; all p < 0.001). Patients in the highest RDW quartile demonstrated the greatest mortality risk, with an adjusted HR of 2.46 for 28-day mortality and 2.65 for 365-day mortality. Kaplan-Meier analysis revealed significantly lower survival probabilities in higher RDW quartiles (log-rank test: p < 0.001). ROC analysis demonstrated fair predictive accuracy for RDW (Area Under the Curve [AUC]: 0.64 for 28-day and 0.68 for 365-day mortality), with optimal cut-off values of 15.35% and 15.55%, respectively. Subgroup analyses confirmed the consistent prognostic value of RDW across most patient strata and identified significant interactions with CKD stage (p for interaction < 0.001) and type 2 diabetes (p for interaction = 0.048).
conclusionRDW is a valuable prognostic biomarker for identifying patients with AF and CKD who are at increased risk of both short- and long-term mortality. This supports its use in risk stratification to guide timely interventions and personalized management. CLINICAL TRIAL NUMBER: not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.